Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial

PURPOSE: Nivolumab is a fully human immunoglobulin G4 programmed death–1 immune checkpoint inhibitor antibody that restores T-cell immune activity. This phase II trial assessed the antitumor activity, dose-response relationship, and safety of nivolumab in patients with metastatic renal cell carcinom...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:J Clin Oncol
मुख्य लेखकों: Motzer, Robert J., Rini, Brian I., McDermott, David F., Redman, Bruce G., Kuzel, Timothy M., Harrison, Michael R., Vaishampayan, Ulka N., Drabkin, Harry A., George, Saby, Logan, Theodore F., Margolin, Kim A., Plimack, Elizabeth R., Lambert, Alexandre M., Waxman, Ian M., Hammers, Hans J.
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: American Society of Clinical Oncology 2015
विषय:
ORIGINAL REPORTS
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC4806782/
https://ncbi.nlm.nih.gov/pubmed/25452452
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2014.59.0703
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन